Clinical Trials Logo
  1. Home
  2. Lipodystrophy
  3. NCT00004329
  4. Details
NCT00004329 Clinical Trial

Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy

Lipodystrophy Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00004329
Other study ID # 199/11884
Secondary ID UTMB-437
Status Completed
Phase N/A
First received October 18, 1999
Last updated June 23, 2005
Start date November 1999

Study information
Verified date December 2003
Source National Center for Research Resources (NCRR)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic receptor in 6 patients with regional lipoatrophy and in 6 controls.

II. Determine the full sequence of the alpha-2 adrenergic receptor structural gene in genomic DNA from peripheral blood leukocytes.

Description:

PROTOCOL OUTLINE: Antihypertensives are held, beginning 3 days before the first study day.

An oral challenge is administered as follows: clonidine on day 1, yohimbine on day 2. The order of administration is reversed in alternate subjects.

Timed measurements of norepinephrine, glycerol, and free fatty acids follow each challenge. Structural gene sequencing is evaluated for each participant.

Recruitment information / eligibility
Status Completed
Enrollment 12
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 65 Years
Eligibility PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Clinical diagnosis of regional lipoatrophy Control subjects: Women aged 18 to 65 Weight 90% to 150% of ideal No significant acute or chronic illness --Patient Characteristics-- Negative pregnancy test required of fertile women

Study Design

Primary Purpose: Screening

Related Conditions & MeSH terms

Locations
Country Name City State
United States University of Texas Medical Branch Galveston Texas

Sponsors (2)
Lead Sponsor Collaborator
National Center for Research Resources (NCRR) University of Texas

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT05419037 - Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
Recruiting NCT03059121 - The Cleveland Cardiometabolic Cohort
Completed NCT00656175 - Raltegravir Therapy for Women With HIV and Fat Accumulation Phase 2
Completed NCT00006185 - Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Phase 1
Completed NCT00202241 - The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS N/A
Recruiting NCT02262832 - Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Phase 3
Completed NCT01679197 - Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Phase 2
Completed NCT02647853 - Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Phase 1
Active, not recruiting NCT00715546 - Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy Phase 1
Completed NCT00069004 - A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth N/A
Completed NCT00025883 - Leptin to Treat Lipodystrophy Phase 2
Completed NCT00001142 - Metabolism and Body Shape of Healthy Children and Children With Chronic Infections N/A
Active, not recruiting NCT02262806 - Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Phase 2
Completed NCT02258685 - Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.
Completed NCT00192621 - Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Phase 4
Completed NCT00006190 - A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Phase 4
Recruiting NCT05930106 - Carotid Doppler Peak Velocity Variation in Liposuction Fluid Management N/A
Recruiting NCT04656054 - Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance
Completed NCT00082628 - Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients Phase 3
Withdrawn NCT01788462 - Egrifta Replacement and Sleep Disordered Breathing N/A